PLENARY KEYNOTE SESSION
WEDNESDAY 11 MARCH 2025, 11:15 AM – 12:20 PM
Current Trends and Opportunities in Bioprocessing
Konstantin B. Konstantinov, PhD, CTO, Ring Therapeutics, Flagship Pioneering
This presentation explores how advances in biology are redefining bioprocessing to enable scalable, efficient, and reproducible manufacturing of emerging therapeutic modalities. By integrating synthetic biology, cell engineering, and data-driven design, the field can move beyond traditional methods toward biologically driven, industrialised platforms. The session highlights how biological innovation underpins the transformation of biomanufacturing for the next generation of complex biologics.
Are We There Yet? A Digital Maturity Model for Enabling Process Monitoring and Artificial Intelligence in Biologics Manufacturing
Jack Prior, PhD, Head, Process Monitoring & Data Science & AI Strategy, Sanofi Group
Digital transformation promises to revolutionise biopharmaceutical manufacturing, yet most organisations leverage a fraction of their process data, with the challenges paradoxically increasing with globalisation and digitisation. This talk presents a practical maturity model for effectively navigating bioprocess monitoring and AI implementation. Drawing on assessments of 25 products, the presentation examines how companies can transform data challenges into competitive advantages by ensuring critical data is made available and delivered effectively.
Biographies
Konstantin B. Konstantinov, PhD, CTO, Ring Therapeutics, Flagship Pioneering
Before joining Ring, Konstantin Konstantinov was responsible for the late-stage bioprocess and technology development at Sanofi’s Boston Hub, including all functions, from cell banking to fill/finish/lyophilization. Prior to Sanofi, Dr. Konstantinov worked for Bayer in Berkeley, California for 14 years, advancing to the position of Head of Process Sciences. He has published 60 peer-reviewed papers and has more than 15 patents and patent applications. During the last 23 years, Dr. Konstantinov has worked on the development and commercialization of various products, including monoclonal antibodies, blood factors and enzymes expressed in mammalian cells. Most recently, he has pioneered the development of an end-to-end integrated continuous biomanufacturing platform, which is becoming a strategic technological trend for the biomanufacturing industry worldwide. Dr. Konstantinov received his PhD in Biochemical Engineering from Osaka University, Japan, which was followed by a post-doctoral assignment at DuPont and the University of Delaware. He is a member of the board of directors for Repligen.
Jack Prior, PhD, Head, Process Monitoring & Data Science & AI Strategy, Sanofi Group
Dr. Jack Prior leads MSAT Process Monitoring & Data Science/AI Strategy at Sanofi, where he spearheads global initiatives in process monitoring and AI-driven yield improvement for biologics manufacturing. Previously as Head of MSAT Digital, he led teams working to develop global process data analytics systems and to digitize laboratory operations for Industrial Affairs Specialty Care drug substance and drug product manufacturing. Jack’s career at Sanofi-Genzyme spans nearly 3 decades, where he has led manufacturing science organizations supporting process characterization, modeling, technology transfer, and manufacturing operations for critical therapies treating rare genetic disorders. Throughout his career, he has focused on integrating process modeling and advanced analytics with manufacturing science to enhance biologics production across US and European operations. Dr. Prior holds a Doctor of Science in Chemical Engineering from MIT and a Bachelor of Science in Chemical Engineering from the University of Connecticut.